Kintara Therapeutics Issues Correction Regarding CVR Issuance Timing For Proposed Merger With TuHURA Biosciences, Now Set For Immediately Before Reverse Stock Split; Merger Expected To Close On October 18, 2024
Portfolio Pulse from Benzinga Newsdesk
Kintara Therapeutics has issued a correction regarding the timing of the Contingent Value Rights (CVR) issuance related to its proposed merger with TuHURA Biosciences. The CVR issuance is now set to occur immediately before a reverse stock split. The merger is expected to close on October 18, 2024.
October 15, 2024 | 8:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Kintara Therapeutics has corrected the timing of its CVR issuance for the merger with TuHURA Biosciences, now set before a reverse stock split. The merger is expected to close on October 18, 2024.
The correction in the timing of the CVR issuance is a significant update for investors as it affects the terms of the merger with TuHURA Biosciences. However, since the merger is still expected to close in 2024, the immediate impact on KTRA's stock price is likely neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 90